Last checked at 
(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.
ViiV Healthcare is a specialist HIV company majority owned by GSK, with Pfizer Inc and Shionogi & Co Ltd as shareholders. GSK is a Brentford, UK-based pharmaceutical maker.
Findings from a Phase One study, which were released by ViiV Healthcare at a conference on Tuesday, showed that an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting, can be dosed at intervals of at least four months.
Data also showed that the intramuscular dosing of CAB-ULA has a safety and pharmacokinetic profile that supports a longer dose interval. According to GSK, these results are ViiV Healthcare's first step towards delivering ultra long-acting injectable HIV treatment and prevention medicines.
ViiV Healthcare is currently conducting a registrational study of CAB-ULA in 2024 to further evaluate its use for the prevention of HIV in adults.
GSK shares were trading 0.4% higher at 1,675.00 pence each in London on Tuesday morning.
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
